Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma [0.03%]
胆道癌新辅助化疗疗效的蛋白基因组预测模型
Hyehyun Jeong,Ji-Hye Oh,Hee-Sung Ahn et al.
Hyehyun Jeong et al.
Background & aims: Cholangiocarcinoma is a heterogeneous disease, and its molecular characteristics and biomarkers and not yet fully understood. Here we performed comprehensive proteogenomic analyses to investigate the mo...
From Long to Snappy and Short Regimens for Paracetamol Overdose: Reinventing the N-Acetyl Cysteine Wheel [0.03%]
从长至简：丙酮酸 overdosage 治疗中的N-乙酰半胱氨酸轮转疗法
Guruprasad P Aithal
Guruprasad P Aithal
Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels [0.03%]
LONP1表达降低通过提高尿嘧啶酸水平加重MASH诱导的肝纤维化
Dengqiu Xu,Zehua Zhang,Ziqi Zhu et al.
Dengqiu Xu et al.
Background & aims: Identifying the metabolic targets driving liver fibrosis in metabolic-dysfunction-associated steatohepatitis (MASH) is essential for developing effective preventive therapies. However, the metabolic pat...
Not all DOACs are created equal, revisiting the safety of rivaroxaban for the prevention of portal hypertension-related complications [0.03%]
并非所有DOACs都一样，重新评估利伐沙班在预防门脉高压相关并发症方面的安全性
Kimberly Kim Bot,Solaiman Ezzafzafi,Marten A Lantinga
Kimberly Kim Bot
Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathy [0.03%]
AAV8基因治疗在线粒体神经胃肠脑肌病肝外体灌注中的成功应用
Teresa Brevini,Lisa Swift,Helen Reynolds et al.
Teresa Brevini et al.
Ex situ normothermic machine perfusion (NMP) is rapidly emerging as a novel platform for testing therapeutics in human donor livers. Recently perfusion of explanted patient livers was achieved, raising the possibility of using these disease...
Corrigendum to: 'CD177+ cells produce neutrophil extracellular traps that promote biliary atresia' (J Hepatol [2022] 77:1299-1310) [0.03%]
“CD177+细胞产生促进胆道闭锁的中性粒细胞胞外陷阱”一文的勘误(2022年第77卷1299-1310页)
Ruizhong Zhang,Liang Su,Ming Fu et al.
Ruizhong Zhang et al.
Published Erratum
Journal of hepatology. 2025 Aug 4:S0168-8278(25)02281-0. DOI:10.1016/j.jhep.2025.06.013 2025
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma [0.03%]
在系统治疗肝细胞癌期间建立肝脱代偿作为有意义的临床结局
Giuseppe Cabibbo,Ciro Celsa,Sherrie Bhoori et al.
Giuseppe Cabibbo et al.
Unlike other solid tumours, the prognosis of patients with advanced hepatocellular carcinoma (HCC) is dually influenced by tumour progression and liver dysfunction. Accumulating evidence suggests that clinically evident hepatic decompensati...
Georg Kramer,Thomas Reiberger,Cristina Ripoll
Georg Kramer
Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: enough, but not too much [0.03%]
肝硬化、腹水和急性肾损伤患者的血浆容量扩张：够用但不过量
Salvatore Piano,Kavish R Patidar,Adrià Juanola;International Club of Ascites GLOBAL AKI team
Salvatore Piano
Can We Trust Self-Reported Drinking Data in Trials of Alcohol-Related Liver Disease? [0.03%]
我们能否相信酒精性肝病临床试验中的饮酒自报数据？
Lingling Meng,Yupeng Di
Lingling Meng